Abstract
Schizophrenia is a chronic, severe, and disabling brain disease. About one-third of all patients with schizophrenia do not respond adequately to drug treatment. Advances in neuroscience and clinical research have led to the introduction of a novel generation of compounds with neuroprotective properties. Despite numerous animal studies with promising neuroprotective agents, no successful strategy for neuroprotection from functional psychoses has been successfully demonstrated. There are two main targets for neuroprotective therapy: (1) neurodegenerative processes in schizophrenia (e.g. apoptosis, excitotoxicity, oxidative stress, stress sensitization, and alteration of neurosteroids); and (2) phenotypic presentations of illness including psychopathological symptoms, significant decline in cognition, psychosocial functioning and in health related quality of life (HRQL). In this chapter substantial information about clinical trials with neurosteroids, vitamins, and some herbal supplements with neuroprotective properties in schizophrenia is presented. Neurosteroids such as pregnenolone (PREG), dehydroepiandrosterone (DHEA) and their sulfates (PREGS and DHEAS) are reported to have a modulatory effect on neuronal excitability and synaptic plasticity. In addition, vitamins and herbal supplements are important for regular cell function, growth and development. As a rule, vitamins promote the activity of enzymes to improve their efficiency and in this role they are called coenzymes. The herbal supplements are active antioxidants with neuroptective properties. The authors hope that neuroprotective strategies will pave the way to the next generation of antipsychotic, sedative and mood stabilizer medications. The clinical effects of neuroprotective agents clearly merit further clinical trials for the treatment of mental disorders.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- AA:
-
Arachidonic acid
- AIMS:
-
Abnormal involuntary movement scale
- BARS:
-
Barnes Akathisia rating scale
- BDNF:
-
Brain-derived neurotrophic factor
- CANTAB:
-
Cambridge automated neuropsychological test battery
- CGI-S:
-
Clinical global impression severity scale
- CNS:
-
Central nervous system
- CSDS:
-
Calgary scale for depression in schizophrenia
- DHA:
-
Docosahexaenoic acid
- DHAs:
-
Docosahexaenoic acids
- DHEA:
-
Dehydroepiandrosterone
- DHEA(S):
-
Both DHEA and DHEAS
- DHEAS:
-
Dehydroepiandrosterone sulfate
- DNA:
-
Deoxyrybonucleic acid
- DPA:
-
Docosapentaenoic acid
- EGb:
-
Extract of gingko biloba
- EPA:
-
Eicosapentaenoic acid
- EPS:
-
Medication-induced extrapyramidal symptoms
- EPUFAs:
-
Essential polyunsaturated fatty acids
- ESRS:
-
Extrapyramidal symptom rating scale
- FGAs:
-
First-generation antipsychotics
- GABA:
-
Gamma-aminobutyric acid
- GABAA :
-
Gamma-aminobutyric acid receptor type A
- HAM-A:
-
Hamilton scale for anxiety
- Hcy:
-
Homoysteine
- HPA:
-
Hypothalamic-pituitary-adrenal axis
- LDL:
-
Low-density lipoprotein
- NMDA:
-
N-methyl-D-aspartate
- PANSS:
-
Positive and negative symptom scale
- PD:
-
Parkinson’s disease
- PREG:
-
Pregnenolone
- PREG(S):
-
Both PREG and PREGS
- PREGS:
-
Pregnenolone sulfate
- PUFA:
-
Polyunsaturated fatty acids
- QLS:
-
Quality of life scale for rating the schizophrenic deficit syndrome
- SAM:
-
S-adenosylmethionine
- SANS:
-
Scale for the assessment of negative symptoms
- SAPS:
-
Scale for the assessment of positive symptoms
- SAS:
-
Simpson-Angus scale
- SD:
-
Standard deviation
- SGAs:
-
Second-generation antipsychotics
- SOD:
-
Superoxide dismutase
- TD:
-
Tardive dyskinesia
References
Berger G, Dell’Olio M, Amminger P et al (2007) Neuroprotection in emerging psychotic disorders. Early Intervent Psychiatry 1:114–127
Ehrenreich H, Siren AL (2001) Neuroprotection–what does it mean?–What means do we have? Eur Arch Psychiatry Clin Neurosci 251:149–151
Jarskog LF, Selinger ES, Lieberman JA, Gilmore JH (2004) Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation. Am J Psychiatry 161:109–115
Krebs M, Leopold K, Hinzpeter A, Schaefer M (2006) Neuroprotective agents in schizophrenia and affective disorders. Expert Opin Pharmacother 7:837–848
Susser E, Ritsner MS (2010) Brain protection in neuropsychiatric disorders: past, present and future challenges. In: Ritsner MS (ed) Brain protection in schizophrenia, mood and cognitive disorders. Springer, Dordrecht, pp 3–25
Ehrenreich H, Aust C, Krampe H et al (2004) Erythropoietin: novel approaches to neuroprotection in human brain disease. Metab Brain Disord 19:195–206
Ritsner MS (2010) Is a neuroprotective therapy suitable for schizophrenia patients? In: Ritsner MS (ed) Brain protection in schizophrenia, mood and cognitive disorders. Springer, Dordrecht, pp 343–395
Niizuma K, Endo H, Chan PH (2009) Oxidative stress and mitochondrial dysfunction as determinants of ischemic neuronal death and survival. J Neurochem 109(Suppl 1):133–138
Csernansky JG (2007) Neurodegeneration in schizophrenia: evidence from in vivo neuroimaging studies. Sci World J 7:135–143
Jarskog LF, Glantz LA, Gilmore JH, Lieberman JA (2005) Apoptotic mechanisms in the pathophysiology of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 29:846–858
Jarskog LF (2006) Apoptosis in schizophrenia: pathophysiologic and therapeutic considerations. Curr Opin Psychiatry 19:307–312
Cadet JL, Kahler LA (1994) Free radical mechanisms in schizophrenia and tardive dyskinesia. Neurosci Biobehav Rev 18:457–467
Warner DS, Sheng H, Batinic-Haberle I (2004) Oxidants antioxidants and the ischemic brain. J Exp Biol 207:3221–3231
Fendri C, Mechri A, Khiari G, Othman A, Kerkeni A, Gaha L (2006) Oxidative stress involvement in schizophrenia pathophysiology: a review. Encephale 32:244–252
Mahadik SP, Scheffer RE (1996) Oxidative injury and potential use of antioxidants in schizophrenia. Prostaglandins Leukot Essent Fatty Acids 55:45–54
Yao JK, Reddy R, McElhinny LG, van Kammen DP (1998) Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr Res 32:1–8
Virit O, Altindag A, Yumru M et al (2009) A defect in the antioxidant defense system in schizophrenia. Neuropsychobiology 60:87–93
Reddy R, Keshavan M, Yao JK (2003) Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophr Res 62:205–212
Smythies JR (1997) Oxidative reactions and schizophrenia: a review-discussion. Schizophr Res 24:357–364
Yao JK, Reddy R, van Kammen DP (1998) Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Res 80:29–39
Yao JK, Reddy R, van Kammen DP (2000) Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. Psychiatry Res 97:137–151
Vardimon L (2000) Neuroprotection by glutamine synthetase. Isr Med Assoc J (Suppl 2):46–51
Deutsch SI, Rosse RB, Schwartz BL, Mastropaolo J (2001) A revised excitotoxic hypothesis of schizophrenia: therapeutic implications. Clin Neuropharmacol 24:43–49
Baulieu EE, Robel P (1998) Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEAS) as neuroactive neurosteroids. Proc Natl Acad Sci USA 95:4089–4091
Charalampopoulos I, Tsatsanis C, Dermitzaki E et al (2004) Dehydroepiandrosterone and allopregnanolone protect sympathoadrenal medulla cells against apoptosis via antiapoptotic Bcl-2 proteins. Proc Natl Acad Sci USA 101:8209–8214
Charalampopoulos I, Tsatsanis C, Margioris AN, Castanas E, Gravanis A (2008) Dehydroepiandrosterone as endogenous inhibitor of neuronal cell apoptosis: potential therapeutic implications in neurodegenerative diseases. In: Ritsner MS, Weizman A (eds) Neuroactive steroids in brain functions, and mental health. New perspectives for research and treatment. Springer, New York, NY, pp 217–225
Gursoy E, Cardounel A, Kalimi M (2001) Pregnenolone protects mouse hippocampal (HT-22) cells against glutamate and amyloid beta protein toxicity. Neurochem Res 26:15–21
Maninger N, Wolkowitz OM, Reus VI, Epel ES, Mellon SH (2009) Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate DHEAS. Front Neuroendocrinol 30:65–91
Naert G, Maurice T, Tapia-Arancibia L, Givalois L (2007) Neuroactive steroids modulate HPA axis activity and cerebral brain-derived neurotrophic factor (BDNF) protein levels in adult male rats. Psychoneuroendocrinology 32:1062–1078
Ritsner MS, Gibel A, Ratner Y, Weizman A (2008) Dehydroepiandrosterone and pregnenolone alterations in schizophrenia. In: Ritsner MS, Weizman A (eds) Neuroactive steroids in brain function, behavior and neuropsychiatric disorders. Novel strategies for research and treatment. Springer, Bazel, pp 251–298
Takahashi Y, Lavigne JA, Hursting SD et al (2004) Using DNA microarray analyses to elucidate the effects of genistein in androgen-responsive prostate cancer cells: identification of novel targets. Mol Carcinog 41:108–119
Akan P, Kizildag S, Ormen M, Genc S, Oktem MA, Fadiloglu M (2009) Pregnenolone protects the PC-12 cell line against amyloid beta peptide toxicity but its sulfate ester does not. Chem Biol Interact 177:65–70
Bastianetto S, Ramassamy C, Poirier J, Quirion R (1999) Dehydroepiandrosterone (DHEA) protects hippocampal cells from oxidative stress-induced damage. Brain Res Mol Brain Res 66:35–41
Cardounel A, Regelson W, Kalimi M (1999) Dehydroepiandrosterone protects hippocampal neurons against neurotoxin-induced cell death: mechanism of action. Proc Soc Exp Biol Med 222:145–149
Karishma KK, Herbert J (2002) Dehydroepiandrosterone (DHEA) stimulates neurogenesis in the hippocampus of the rat, promotes survival of newly formed neurons and prevents corticosterone-induced suppression. Eur J Neurosci 16:445–453
Kimonides VG, Khatibi NH, Svendsen CN, Sofroniew MV, Herbert J (1998) Dehydroepiandrosterone(DHEA) and DHEA-sulfate (DHEAS) protect hippocampal neurons against excitatory amino acid-induced neurotoxicity. Proc Natl Acad Sci USA 95:1852–1857
Kurata K, Takebayashi M, Morinobu S, Yamawaki S (2004) beta-estradiol, dehydroepiandrosterone, and dehydroepiandrosterone sulfate protect against N-methyl-D-aspartate-induced neurotoxicity in rat hippocampal neurons by different mechanisms. J Pharmacol Exp Ther 311:237–245
Leskiewicz M, Jantas D, Budziszewska B, Lason W (2008) Excitatory neurosteroids attenuate apoptotic and excitotoxic cell death in primary cortical neurons. J Physiol Pharmacol 59:457–475
Veiga S, Garcia-Segura LM, Azcoitia I (2003) Neuroprotection by the steroids pregnenolone and dehydroepiandrosterone is mediated by the enzyme aromatase. J Neurobiol 56:398–406
Gallagher P, Ritsner MS (2009) Can the cortisol to DHEA molar ratio be used as a peripheral biomarker for schizophrenia and mood disorders? In: Ritsner MS (ed) The Handbook of neuropsychiatric biomarkers, endophenotypes and genes, vol 3, Springer, Dordrecht, pp 27–45
Ritsner M, Maayan R, Gibel A, Strous RD, Modai I, Weizman A (2004) Elevation of the cortisol/dehydroepiandrosterone ratio in schizophrenia patients. Eur Neuropsychopharmacol 14:267–273
Ritsner MS (ed) (2008) Neuroactive steroids in brain functions, and mental health. New perspectives for research and treatment. Springer, New York, NY
Nachshoni T, Ebert T, Abramovitch Y et al (2005) Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: a randomized, double-blind placebo controlled trial. Schizophr Res 79:251–256
Ritsner MS, Gibel A, Ratner Y, Tsinovoy G, Strous RD (2006) Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychopharmacol 26:495–499
Ritsner MS, Strous RD (2009) Neurocognitive deficits in schizophrenia are associated with alterations in blood levels of neurosteroids: a multiple regression analysis of findings from a double-blind, randomized, placebo-controlled, crossover trial with DHEA. J Psychiatr Res 44:75–80
Strous RD, Gibel A, Maayan R, Weizman A, Ritsner MS (2008) Hormonal response to dehydroepiandrosterone administration in schizophrenia: findings from a randomized, double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol 28:456–459
Strous RD, Maayan R, Lapidus R et al (2003) Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch Gen Psychiatry 60:133–141
Strous RD, Stryjer R, Maayan R et al (2007) Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial. Psychoneuroendocrinology 32:96–105
Nestler JE, Barlascini CO, Clore JN, Blackard WG (1988) Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J Clin Endocrinol Metab 66:57–61
Ritsner M, Gibel A, Ram E, Maayan R, Weizman A (2006) Alterations in DHEA metabolism in schizophrenia: two-month case-control study. Eur Neuropsychopharmacol 16:137–146
Ritsner MS, Gibel A, Shleifer T et al (2010) Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia: an 8-week, double-blind, randomized, controlled, two-center, parallel-group study. J Clin Psychiatry 71(10):1351–1362
Marx CE, Keefe RS, Buchanan RW et al (2009) Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacol 34:1885–1903
Zempleni J, Rucker RB, Suttie JW, McCormick DB (eds) (2007) Handbook of vitamins, 4th edn. CRC Press, New York, NY
Combs GF (2008) The vitamins: fundamental aspects in nutrition and health, 3rd edn. Elsevier Academic Press, Burlington
Sato Y, Meller R, Yang T, Taki W, Simon RP (2008) Stereo-selective neuroprotection against stroke with vitamin A derivatives. Brain Res 1241:188–192
Malaspina A, Michael-Titus AT (2008) Is the modulation of retinoid and retinoid-associated signaling a future therapeutic strategy in neurological trauma and neurodegeneration? J Neurochem 104:584–595
McCaffery P, Drager DC (1994) High level of a retinoic acid-generating dehydrogenase in the meso telencephalic dopamine system. Proc Natl Acad Sci USA 91:7772–7776
Nau H, Chahoud I, Dencker L, Lammer RJ, Scott WI (1994) Teratogenicity of vitamin A and retinoids. In: Blomhoff R (ed) Vitamin A in health and disease. Dekker, New York, NY, pp 615–663
Satre MA, Ugen KE, Kochhar DM (1992) Developmental changes in endogenous retinoids during pregnancy and embryogenesis in the mouse. Biol Reprod 46:802–810
Wagner E, Luo T, Drager UC (2002) Retinoic acid synthesis in the postnatal mouse brain marks distinct developmental stages and functional systems. Cereb Cortex 12:1244–1253
Arinami T, Gao M, Hamaguchi H, Toru M (1997) A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 6:577–582
Balmer JE, Blomhoff R (2002) Gene expression regulation by retinoic acid. J Lipid Res 43:1773–1808
Krezel W, Ghyselinck N, Samad TA et al (1998) Impaired locomotion and dopamine signaling in retinoid receptor mutant mice. Science 279:863–867
Samad TA, Krezel W, Chambon P, Borrelli E (1997) Regulation of dopaminergic pathways by retinoids: activation of the D2 receptor promoter by members of the retinoic acid receptor-retinoid X receptor family. Proc Natl Acad Sci USA 94:14349–14354
Goodman AB (1998) Three independent lines of evidence suggest retinoids as causal to schizophrenia. Proc Natl Acad Sci USA 95:7240–7244
Goodman AB (2005) Microarray results suggest altered transport and lowered synthesis of retinoic acid in schizophrenia. Mol Psychiatry 10:620–621
Etchamendy N, Enderlin V, Marighetto A, Pallet V, Higueret P, Jaffard R (2003) Vitamin A deficiency and relational memory deficit in adult mice: relationships with changes in brain retinoid signalling. Behav Brain Res 145:37–49
Misner DL, Jacobs S, Shimizu Y et al (2001) Vitamin deprivation results in reversible loss of hippocampal long-term synaptic plasticity. Proc Natl Acad Sci USA 98:11714–11719
Alfos S, Boucheron C, Pallet V et al (2001) A retinoic acid receptor antagonist suppresses brain retinoic acid receptor overexpression and reverses a working memory deficit induced by chronic ethanol consumption in mice. Alcohol Clin Exp Res 25:1506–1514
Corcoran JP, So PL, Maden M (2004) Disruption of the retinoid signalling pathway causes a deposition of amyloid beta in the adult rat brain. Eur J Neurosci 20:896–902
Goodman AB, Pardee AB (2003) Evidence for defective retinoid transport and function in late onset Alzheimer’s disease. Proc Natl Acad Sci USA 100:2901–2905
Lane MA, Bailey SJ (2005) Role of retinoid signalling in the adult brain. Prog Neurobiol 75:275–293
Mey J, McCaffery P (2004) Retinoic acid signaling in the nervous system of adult vertebrates. Neuroscientist 10:409–421
Lerner V, Miodownik C, Gibel A et al (2008) Bexarotene as add-on to antipsychotic treatment in schizophrenia patients: a pilot open-label trial. Clin Neuropharmacol 31:25–33
Bucci L (1973) Pyridoxine and schizophrenia. Br J Psychiatry 122:240
Brooks SC, D’Angelo L, Chalmeta A, Ahern G, Judson JH (1983) An unusual schizophrenic illness responsive to pyridoxine HCl (B6) subsequent to phenothiazine and butyrophenone toxicities. Biol Psychiatry 18:1321–1328
Lerner V, Liberman M (1998) Movement disorders and psychotic symptoms treated with pyridoxine: a case report [letter]. J Clin Psychiatry 59:623–624
Sandyk R, Pardeshi R (1990) Pyridoxine improves drug-induced parkinsonism and psychosis in a schizophrenic patient. Int J Neurosci 52(3–4):225–232
Petrie WM, Ban TA, Ananth JV (1981) The use of nicotinic acid and pyridoxine in the treatment of schizophrenia. Int Pharmacopsychiatry 16:245–250
Ananth JV, Ban TA, Lehmann HE (1973) Potentiation of therapeutic effects of nicotinic acid by pyridoxine in chronic schizophrenics. Can Psychiatr Assoc J 18:377–383
Ban TA, Lehmann HE, Deutsch M (1977) Negative findings with megavitamins in schizophrenic patients: preliminary report. Commun Psychopharmacol 1:119–122
Lerner V, Miodownik C, Kaptsan A, Cohen H, Loewenthal U, Kotler M (2002) Vitamin B6 as add-on treatment in chronic schizophrenic and schizoaffective patients: a double-blind, placebo-controlled study. J Clin Psychiatry 63:54–58
Rebec GV, Centore JM, White LK, Alloway KD (1985) Ascorbic acid and the behavioral response to haloperidol: implications for the action of antipsychotic drugs. Science 227:438–440
Singh RB, Ghosh S, Niaz MA et al (1995) Dietary intake, plasma levels of antioxidant vitamins, and oxidative stress in relation to coronary artery disease in elderly subjects. Am J Cardiol 76:1233–1238
Suboticanec K (1986) Vitamin C status in schizophrenia. Bibl Nutr Dieta 173–181
Suboticanec K, Folnegovic-Smalc V, Korbar M, Mestrovic B, Buzina R (1990) Vitamin C status in chronic schizophrenia. Biol Psychiatry 28:959–966
Milner G (1963) Ascorbic acid in chronic psychiatric patients: a controlled trial. Br J Psychiatry 109:294–299
Beauclair L, Vinogradov S, Riney SJ, Csernansky JG, Hollister LE (1987) An adjunctive role for ascorbic acid in the treatment of schizophrenia? J Clin Psychopharmacol 7:282–283
Sandyk R, Kanofsky JD (1993) Vitamin C in the treatment of schizophrenia. Int J Neurosci 68:67–71
Smythies JR (1996) The role of ascorbate in brain: therapeutic implications. J R Soc Med 89:241
Dakhale GN, Khanzode SD, Khanzode SS, Saoji A (2005) Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Psychopharmacology (Berl) 182:494–498
Arvindakshan M, Ghate M, Ranjekar PK, Evans DR, Mahadik SP (2003) Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr Res 62:195–204
McGrath J, Saari K, Hakko H et al (2004) Vitamin D supplementation during the first year of life and risk of schizophrenia: a Finnish birth cohort study. Schizophr Res 67:237–245
Becker A, Eyles DW, McGrath JJ, Grecksch G (2005) Transient prenatal vitamin D deficiency is associated with subtle alterations in learning and memory functions in adult rats. Behav Brain Res 161:306–312
Yan J, Feng J, Craddock N et al (2005) Vitamin D receptor variants in 192 patients with schizophrenia and other psychiatric diseases. Neurosci Lett 380:37–41
McGrath J (1999) Hypothesis: is low prenatal vitamin D a risk-modifying factor for schizophrenia? Schizophr Res 40:173–177
Garcion E, Wion-Barbot N, Montero-Menei CN, Berger F, Wion D (2002) New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab 13:100–105
Kalueff AV, Eremin KO, Tuohimaa P (2004) Mechanisms of neuroprotective action of vitamin D(3). Biochemistry (Moscow) 69:738–741
Kiraly SJ, Kiraly MA, Hawe RD, Makhani N (2006) Vitamin D as a neuroactive substance: review. Sci World J 6:125–139
Llewellyn DJ, Langa K, Lang I (2009) Serum 25-Hydroxyvitamin D Concentration and Cognitive Impairment. J Geriatr Psychiatry Neurol 22(3):188–195
Wilkins CH, Sheline YI, Roe CM, Birge SJ, Morris JC (2006) Vitamin D deficiency is associated with low mood and worse cognitive performance in older adults. Am J Geriatr Psychiatry 14:1032–1040
Armstrong DJ, Meenagh GK, Bickle I, Lee AS, Curran ES, Finch MB (2007) Vitamin D deficiency is associated with anxiety and depression in fibromyalgia. Clin Rheumatol 26:551–554
Berk M, Sanders KM, Pasco JA et al (2007) Vitamin D deficiency may play a role in depression. Med Hypotheses 69:1316–1319
Grant WB (2009) Does vitamin D reduce the risk of dementia? J Alzheimers Dis 17:151–159
Osakada F, Hashino A, Kume T, Katsuki H, Kaneko S, Akaike A (2004) Alpha-tocotrienol provides the most potent neuroprotection among vitamin E analogs on cultured striatal neurons. Neuropharmacology 47:904–915
Osakada F, Hashino A, Kume T, Katsuki H, Kaneko S, Akaike A (2003) Neuroprotective effects of alpha-tocopherol on oxidative stress in rat striatal cultures. Eur J Pharmacol 465:15–22
Roghani M, Behzadi G (2001) Neuroprotective effect of vitamin E on the early model of Parkinson’s disease in rat: behavioral and histochemical evidence. Brain Res 892:211–217
Post A, Rucker M, Ohl F et al (2002) Mechanisms underlying the protective potential of alpha-tocopherol (vitamin E) against haloperidol-associated neurotoxicity. Neuropsychopharmacology 26:397–407
D’Souza B, D’Souza V (2003) Oxidative injury and antioxidant vitamins E and C in schizophrenia. Ind J Clin Biochem 18:87–90
Bottiglieri T (1996) Folate vitamin B12, and neuropsychiatric disorders. Nutr Rev 54:382–390
Bottiglieri T, Hyland K, Laundy M et al (1992) Folate deficiency, biopterin and monoamine metabolism in depression. Psychol Med 22:871–876
Hutto BR (1997) Folate and cobalamin in psychiatric illness. Compr Psychiatry 38:305–314
Anonymous (1998) Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists’ Collaboration. Br Med J 316:894–898
Brouwer IA, van Dusseldorp M, Duran M et al (1999) Low-dose folic acid supplementation does not influence plasma methionine concentrations in young non-pregnant women. Br J Nutr 82:85–89
Stabler SP, Marcell PD, Podell ER, Allen RH, Savage DG, Lindenbaum J (1988) Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatography-mass spectrometry. J Clin Invest 81:466–474
Akaike A, Tamura Y, Sato Y, Yokota T (1993) Protective effects of a vitamin B12 analog, methylcobalamin, against glutamate cytotoxicity in cultured cortical neurons. Eur J Pharmacol 241:1–6
Hector M, Burton JR (1988) What are the psychiatric manifestations of vitamin B12 deficiency? [see comments]. J Am Geriatr Soc 36:1105–1112
Silver H (2000) Vitamin B12 levels are low in hospitalized psychiatric patients. Isr J Psychiatry Relat Sci 37:41–45
de Carvalho MJ, Guilland JC, Moreau D, Boggio V, Fuchs F (1996) Vitamin status of healthy subjects in Burgundy (France). Ann Nutr Metab 40:24–51
Garry PJ, Goodwin JS, Hunt WC (1984) Folate and vitamin B12 status in a healthy elderly population. J Am Geriatr Soc 32:719–726
Grinblat J, Marcus DL, Hernandez F, Freedman ML (1986) Folate and vitamin B12 levels in an urban elderly population with chronic diseases. Assessment of two laboratory folate assays: microbiologic and radioassay. J Am Geriatr Soc 34:627–632
Beck WS (1991) Neuropsychiatric consequences of cobalamin deficiency. Adv Intern Med 36:33–56
Brett AS, Roberts MS (1994) Screening for vitamin B12 deficiency in psychiatric patients. J Gen Intern Med 9:522–524
Buchman N, Mendelsson E, Lerner V, Kotler M (1999) Delirium associated with vitamin B12 deficiency after pneumonia. Clin Neuropharmacol 22:356–358
Burvill PW, Jackson JM, Smith WG (1969) Psychiatric symptoms due to vitamin B12 deficiency without anaemia. Med J Aust 2:388–390
Dommisse J (1991) Subtle vitamin-B12 deficiency and psychiatry: a largely unnoticed but devastating relationship? Med Hypotheses 34:131–140
Hansen T, Rafaelson O, Rodbro P (1966) Vitamin B12 deficiency in psychiatry. Lancet 2:965
Levitt AJ, Joffe RT (1988) Vitamin B12 in psychotic depression. Br J Psychiatry 153:266–267
Lindenbaum J, Healton EB, Savage DG et al (1988) Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. New Engl J Med 318:1720–1728
Modell S, Naber D, Muller-Spahn F (1993) [Paranoid psychosis in a patient with hypothyroidism and vitamin B12 deficiency]. Nervenarzt 64:340–342
Zucker DK, Livingston RL, Nakra R, Clayton PJ (1981) B12 deficiency and psychiatric disorders: case report and literature review. Biol Psychiatry 16:197–205
Lerner V, Kanevsky M, Dwolatzky T, Rouach T, Kamin R, Miodownik C (2006) Vitamin B12 and folate serum levels in newly admitted psychiatric patients. Clin Nutr 25:60–67
Regland B, Johansson BV, Gottfries CG (1994) Homocysteinemia and schizophrenia as a case of methylation deficiency. J Neural Transm Gen Sect 98:143–152
Carney MW, Sheffield BF (1978) Serum folic acid and B12 in 272 psychiatric in-patients. Psychol Med 8:139–144
Godfrey PS, Toone BK, Carney MW et al (1990) Enhancement of recovery from psychiatric illness by methylfolate. Lancet 336:392–395
Levine J, Stahl Z, Sela BA et al (2006) Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Biol Psychiatry 60:265–269
Freeman MP (2000) Omega-3 fatty acids in psychiatry: a review. Ann Clin Psychiatry 12:159–165
Peet M (2008) Omega-3 polyunsaturated fatty acids in the treatment of schizophrenia. Isr J Psychiatry Relat Sci 45:19–25
Mellor JE, Laugharne JD, Peet M (1996) Omega-3 fatty acid supplementation in schizophrenic patients. Human Psychopharmacol 11:39–46
Peet M, Brind J, Ramchand CN, Shah S, Vankar GK (2001) Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res 49:243–251
Amminger GP, Schafer MR, Papageorgiou K et al (2010) Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 67:146–154
Berger GE, Proffitt TM, McConchie M et al (2007) Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial. J Clin Psychiatry 68:1867–1875
Emsley R, Myburgh C, Oosthuizen P, van Rensburg SJ (2002) Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry 159:1596–1598
Peet M, Horrobin DF (2002) A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res 36:7–18
Emsley R, Niehaus DJ, Koen L et al (2006) The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial. Schizophr Res 84:112–120
Fenton WS, Dickerson F, Boronow J, Hibbeln JR, Knable M (2001) A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 158:2071–2074
Bentsen H (2006) The Norwegian study on the treatment of schizophrenia and schizoaffective disorder with ethyl-EPA and antioxidants. The Second Conference on Brain Phospholipids. Aviemore, Scotland
McKenna DJ, Jones K, Hughes K (2001) Efficacy safety, and use of ginkgo biloba in clinical and preclinical applications. Altern Ther Health Med 7(70–86):88–90
Smith JV, Luo Y (2004) Studies on molecular mechanisms of Ginkgo biloba extract. Appl Microbiol Biotechnol 64:465–472
DeFeudis FV, Drieu K (2000) Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Curr Drug Targets 1:25–58
Ramassamy C, Longpre F, Christen Y (2007) Ginkgo biloba extract (EGb 761) in Alzheimer’s disease: is there any evidence? Curr Alzheimer Res 4:253–262
Zhou D, Zhang X, Su J et al (1999) The effects of classic antipsychotic haloperidol plus the extract of ginkgo biloba on superoxide dismutase in patients with chronic refractory schizophrenia. Chin Med J (Engl) 112:1093–1096
Atmaca M, Tezcan E, Kuloglu M, Ustundag B, Kirtas O (2005) The effect of extract of ginkgo biloba addition to olanzapine on therapeutic effect and antioxidant enzyme levels in patients with schizophrenia. Psychiatry Clin Neurosci 59:652–656
Knable MB (2002) Extract of Ginkgo biloba added to haloperidol was effective for positive symptoms in refractory schizophrenia. Evid Based Ment Health 5:90
Zhang XY, Zhou DF, Zhang PY, Wu GY, Su JM, Cao LY (2001) A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. J Clin Psychiatry 62:878–883
Zhang XY, Zhou DF, Cao LY, Wu GY (2006) The effects of Ginkgo biloba extract added to haloperidol on peripheral T cell subsets in drug-free schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology (Berl) 188:12–17
Ekborg-Ott KH, Taylor A, Armstrong DW (1997) Varietal differences in the total and enantiomeric composition of theanine in tea. J Agric Food Chem 45:353–363
Bryan J (2008) Psychological effects of dietary components of tea: caffeine and L-theanine. Nutr Rev 66:82–90
Nathan PJ, Lu K, Gray M, Oliver C (2006) The neuropharmacology of L-theanine(N-ethyl-L-glutamine): a possible neuroprotective and cognitive enhancing agent. J Herb Pharmacother 6:21–30
Yamada T, Terashima T, Okubo T, Juneja LR, Yokogoshi H (2005) Effects of theanine, r-glutamylethylamide, on neurotransmitter release and its relationship with glutamic acid neurotransmission. Nutr Neurosci 8:219–226
Egashira N, Hayakawa K, Osajima M et al (2007) Involvement of GABA(A) receptors in the neuroprotective effect of theanine on focal cerebral ischemia in mice. J Pharmacol Sci 105:211–214
Kakuda T, Nozawa A, Sugimoto A, Niino H (2002) Inhibition by theanine of binding of [3H]AMPA, [3H]kainate, and [3H]MDL 105,519 to glutamate receptors. Biosci Biotechnol Biochem 66:2683–2686
Yokozawa T, Dong E (1997) Influence of green tea and its three major components upon low-density lipoprotein oxidation. Exp Toxicol Pathol 49:329–335
Yokogoshi H, Kobayashi M, Mochizuki M, Terashima T (1998) Effect of theanine, r-glutamylethylamide, on brain monoamines and striatal dopamine release in conscious rats. Neurochem Res 23:667–673
Terashima T, Takido J, Yokogoshi H (1999) Time-dependent changes of amino acids in the serum, liver, brain and urine of rats administered with theanine. Biosci Biotechnol Biochem 63:615–618
Tsuge H, Sano S, Hayakawa T, Kakuda T, Unno T (2003) Theanine gamma-glutamylethylamide, is metabolized by renal phosphate-independent glutaminase. Biochim Biophys Acta 1620:47–53
Sadzuka Y, Sugiyama T, Nagamine M, Umegaki K, Sonobe T (2006) Efficacy of theanine is connected with theanine metabolism by any enzyme, not only drug metabolizing enzymes. Food Chem Toxicol 44:286–292
Juneja LR, Chu DC, Okubo T, Nagato Y, Yokogoshi H (1999) L-theanine-a unique amino acid of green tea and its relaxation effect in humans. Trends Food Sci Technol 10:199–204
Lu K, Gray MA, Oliver C et al (2004) The acute effects of L-theanine in comparison with alprazolam on anticipatory anxiety in humans. Hum Psychopharmacol 19:457–465
Kakuda T, Matsuura T, Sagesaka Y, Kawasaki T, Inventors (1996); Product and method for inhibiting caffeine stimulation with theanine. USA
Kakuda T, Nozawa A, Unno T, Okamura N, Okai O (2000) Inhibiting effects of theanine on caffeine stimulation evaluated by EEG in the rat. Biosci Biotechnol Biochem 64:287–293
Kent JM, Mathew SJ, Gorman JM (2002) Molecular targets in the treatment of anxiety. Biol Psychiatry 52:1008–1030
Ito K, Nagato Y, Aoi N et al (1998) Effects of L-theanine on the release of alpha-brain waves in human volunteers. Nippon Nogeikagaku Kaishi 72:153–157
Yokogoshi H, Mochizuki M, Saitoh K (1998) Theanine-induced reduction of brain serotonin concentration in rats. Biosci Biotechnol Biochem 62:816–817
Kobayashi K, Nagato Y, Aoi N et al (1998) Effects of L-theanine on the release of α-brain waves in human volunteers. Nippon Nogeikagaku Kaishi 72:153–157
Acknowledgments
We thank our collaborators Dr. Anatoly Gibel, Dr. Ekateryna Kovalyonok, Dr. Chanoch Miodownik, Dr. Yael Ratner, Dr. Tatyana Shleifer and Professor Abraham Weizman in the reviewed studies for fruitful cooperation. DHEA, L-theanine and vitamin B6 studies were supported by grants from the Stanley Foundation.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Ritsner, M.S., Lerner, V. (2011). Advancing Neuroprotective-Based Treatments for Schizophrenia. In: Ritsner, M. (eds) Handbook of Schizophrenia Spectrum Disorders, Volume III. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-0834-1_3
Download citation
DOI: https://doi.org/10.1007/978-94-007-0834-1_3
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-0833-4
Online ISBN: 978-94-007-0834-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)